University Hospital Augsburg
Augsburg, 86165, Germany
NCT Number: NCT06037525
Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Augsburg, 86165, Germany
Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases. The selected patients are in need of a long-term i.v. therapy for reasons as antibiotic therapy or alprostadil therapy. The Midline catheter is a device, which is placed via Seldinger's technique to a vein usual on the upper extremity under ultrasound-control.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
Time frame: 0-29 days
Length of catheter in situ time
Time frame: 0-29 days
Feasibility for the usage of Alprostadil measured by patients with development of thrombophlebitis or occlusion
Time frame: 0-29 days
Site complications as thrombophlebitis and occlusion
University Hospital Augsburg
Other
Acronym: Midline
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07025161
Neurologic Manifestations, Pain
Orlando, Florida, United States
View Trial DetailsNCT05283980
Acute Pain, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT06869369
Behavior, Motor Activity
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT07729020
Anxiety, Anxiety Disorders
Genoa, Liguria, Italy
View Trial Details